A Phase I Study to Investigate the ADME of KD101

NCT02819934 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2020-03-19

No results posted yet for this study

Summary

A Phase I Study to Investigate the Absorption, Metabolism, and Excretion of KD101 in Male Subjects

Conditions

Interventions

DRUG

KD101

after 10 min KD101 administered, 14C KD101 3.52ug/1ml administrated. both of them will be administrate for oral

Sponsors & Collaborators

  • Seoul National University Hospital

    lead OTHER

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Max Age
55 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-05-20
Primary Completion
2016-06-06
Completion
2018-12-15

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02819934 on ClinicalTrials.gov